Nektar Therapeutics (NKTR) Equity Average (2011 - 2026)

Nektar Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at $333.0 million for Q1 2026.

• In Q1 2026, Equity Average rose 794.32% year-over-year to $333.0 million; the TTM figure through Mar 2026 stood at $333.0 million (up 794.32% YoY), while the FY2025 annual figure was $75.3 million, down 21.47% from the prior year.
• Equity Average was $333.0 million for Q1 2026 at Nektar Therapeutics, up from $87.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $643.7 million in Q1 2022 to a low of -$5.2 million in Q2 2025.
• Historically, Equity Average has averaged $216.6 million across 5 years, with a median of $145.2 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Equity Average sank 105.07% in 2025, then surged 794.32% in 2026.
• A 5-year view of Equity Average shows it stood at $389.4 million in 2022, then sank by 62.72% to $145.2 million in 2023, then plunged by 62.25% to $54.8 million in 2024, then surged by 59.57% to $87.5 million in 2025, then soared by 280.78% to $333.0 million in 2026.
• The last three Equity Average figures came in at $333.0 million (Q1 2026), $87.5 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.